TL;DR
The commercial obesity market is intensifying as the battleground expands from injectable volume to oral market share and legal arenas. While Novo Nordisk's oral Wegovy pill has established massive volume dominance, the company is facing aggressive direct-to-consumer advertising from Eli Lilly, sparking federal litigation. Meanwhile, Amgen is rapidly advancing its multi-indication Phase 3 pipeline for MariTide to challenge the established incumbents with less frequent dosing regimens.
The Oral GLP-1 Market Solidifies Around Novo's Massive Early Lead
The commercial race for daily oral weight-loss therapies is rapidly consolidating around a dominant first mover, even as new competitors enter the market.
"The Wegovy pill is the strongest-ever GLP-1 launch by volume, and we have now reached over 5 million total prescriptions... In the face of competition launched in early April, the Wegovy pill has captured around 90% of the oral obesity medication market." — Novo Nordisk Q2 2026 Earnings Call Transcript via eli-lilly-foundayo-orforglipron-fda-approval
"Lilly’s newly launched obesity pill, Foundayo, which won U.S. approval in April, took in $98 million in sales for the second quarter." — Eli Lilly Q2 2026 Earnings Release via eli-lilly-foundayo-orforglipron-fda-approval
This early commercial divergence highlights the immense power of Novo Nordisk's head start, with its oral formulation capturing approximately 90% of the U.S. oral obesity market and exceeding 5 million total prescriptions since its January 5, 2026 launch eli-lilly-foundayo-orforglipron-fda-approval. Although Eli Lilly's Foundayo generated a modest $98 million in its debut quarter, Lilly's overall unit volume growth of 37% and blowout total revenue of $22.97 billion demonstrate that the broader market has ample room for both giants to thrive eli-lilly-foundayo-orforglipron-fda-approval
.
What to watch: Watch how Novo Nordisk's aggressive international expansion of the Wegovy Pill, including its scheduled September 2026 commercial launch in Germany, impacts its global volume trajectory eli-lilly-foundayo-orforglipron-fda-approval.
Marketing Claims Become the New Legal Battleground for Market Share
The commercial rivalry between the leading GLP-1 manufacturers has escalated into federal court as they fight to control the narrative around clinical efficacy and dosing.
"Healthcare companies have a responsibility to keep their public claims accurate and current — ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns." — John F. Kuckelman, Novo Nordisk's Senior Vice President and Group General Counsel via novo-nordisk-eli-lilly-advertising-lawsuit
"Rather than compete on the merits of its products, Novo Nordisk is asking a court to stop Eli Lilly from communicating the results of that trial. We stand firmly behind our advertising. It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available — exactly what patients deserve." — Eli Lilly Spokesperson via novo-nordisk-eli-lilly-advertising-lawsuit
This legal dispute underscores that commercial dominance is no longer just about clinical outcomes, but how those outcomes are framed to the public. Novo Nordisk's lawsuit, filed on July 21, 2026, alleges that Lilly's national campaigns are deceptive because they compare Lilly's highest doses to lower, outdated doses of Novo's therapies, ignoring Novo's newly approved higher doses like Wegovy 7.2 mg novo-nordisk-eli-lilly-advertising-lawsuit. Lilly's defense rests heavily on its SURMOUNT-5 trial, which remains the only randomized, head-to-head clinical trial directly comparing Zepbound and Wegovy [novo-nordisk-eli-lilly-advertising-lawsuit](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f/notes/novo-nordisk-eli-lilly-advertising-lawsuit].
What to watch: Watch for a ruling on Novo Nordisk's threatened motion for an immediate preliminary injunction, which could force Lilly to pull its national advertising campaigns novo-nordisk-eli-lilly-advertising-lawsuit.
Amgen Positions MariTide to Challenge the Incumbent Duopoly
The next wave of obesity therapeutics is advancing rapidly through clinical trials, with developers targeting broad therapeutic indications to rival established leaders.
"Amgen's Q2 results reflect strong performance across our business, with total revenues increasing 10% to $10.1 billion." — Amgen Q2 2026 Earnings Release via amgen-maritide-phase-2-results-maritime-phase-3
"The Phase III trial evaluating MariTide in overweight or obese patients living with Type 2 diabetes (T2D) is also active and progressing." — Amgen MARITIME Clinical Trials via amgen-maritide-phase-2-results-maritime-phase-3
Amgen is aggressively positioning MariTide as a major market disruptor by launching a comprehensive clinical program that targets not just obesity, but also cardiovascular outcomes, heart failure, and obstructive sleep apnea amgen-maritide-phase-2-results-maritime-phase-3. By focusing on optimized dose escalation protocols in its MARITIME-1 study, Amgen is directly addressing the gastrointestinal tolerability issues that have plagued early-generation GLP-1 therapies amgen-maritide-phase-2-results-maritime-phase-3
. This clinical push, backed by a 10% year-over-year revenue increase to $10.1 billion, represents the most serious threat to Lilly and Novo's market dominance amgen-maritide-phase-2-results-maritime-phase-3
.
What to watch: Watch for the resolution of Amgen's ongoing IRS Tax Court litigation, expected no earlier than the second half of 2026, which could significantly impact its capital allocation strategy amgen-maritide-phase-2-results-maritime-phase-3.
What surprised us
- Novo's Ziltivekimab Phase 3 Failure: It is highly surprising that ziltivekimab completely failed to reduce cardiovascular events in the Phase III ZEUS trial, yielding a disappointing hazard ratio of 0.99 despite successfully engaging its target and reducing systemic inflammation novo-nordisk-cardiovascular-pipeline-ziltivekimab
.
- The Clinical Disconnect of IL-6 Inhibition: The ZEUS trial revealed a stark, unexpected disconnect: reducing hsCRP and free IL-6 did not translate into clinical efficacy, but did result in a higher rate of serious infections due to systemic immunosuppression novo-nordisk-cardiovascular-pipeline-ziltivekimab
- Novo's 90% Oral Market Share Lock: Despite Eli Lilly's massive commercial footprint, Novo Nordisk managed to capture a staggering 90% of the U.S. oral obesity market in just over 30 weeks following the launch of its Wegovy Pill eli-lilly-foundayo-orforglipron-fda-approval
.
Open threads worth a vote
[watch] Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads)